N'-[(2-hydroxynaphthalen-1-yl)methylidene]-3-(naphthalen-2-yl)-1H-pyrazole-5-carbohydrazide | 306301-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N'-[(2-hydroxynaphthalen-1-yl)methylidene]-3-(naphthalen-2-yl)-1H-pyrazole-5-carbohydrazide
• 英文别名: N-[(Z)-(2-hydroxynaphthalen-1-yl)methylideneamino]-3-naphthalen-2-yl-1H-pyrazole-5-carboxamide
• CAS: 306301-68-8
• 化学式: C₂₅H₁₈N₄O₂
• 分子量: 406.4
• InChiKey: XOXCTLAKMCIWCF-YSMPRRRNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Methods for enhancing the potency of the immune checkpoint inhibitors
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10822415B2

  公开（公告）日：2020-11-03

  The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

  本发明涉及增强免疫检查点抑制剂效力的方法。特别是，本发明涉及一种增强作为治疗方案一部分施用给受试者的免疫检查点抑制剂效力的方法，该方法包括将药学有效量的SK1抑制剂与免疫检查点抑制剂联合施用给受试者。
• METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3407912A1

  公开（公告）日：2018-12-05
• [EN] METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS<br/>[FR] MÉTHODES PERMETTANT D'AMÉLIORER LA PUISSANCE D'INHIBITEURS DE POINTS DE CONTRÔLE IMMUNITAIRES
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017129769A1

  公开（公告）日：2017-08-03

  The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.